MAST ERLE T 4

4 · ZOGENIX, INC. · Filed Jan 21, 2022

Form 4

Period: 2022-01-19

Director

Transactions

Exercise/Conversion
Stock Option (Right to Buy)
2022-01-19−4,375→ 1,250 total
Exercise: $12.00Exp: 2023-06-18→ Common Stock (4,375 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2022-01-19$15.04/sh+6,250$94,000→ 9,277 total
Exercise/Conversion
Stock Option (Right to Buy)
2022-01-19$12.00/sh+4,375$52,500→ 18,027 total
Exercise/Conversion
Stock Option (Right to Buy)
2022-01-19−6,250→ 0 total
Exercise: $15.04Exp: 2022-04-27→ Common Stock (6,250 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2022-01-19−4,375→ 0 total
Exercise: $14.88Exp: 2022-06-06→ Common Stock (4,375 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2022-01-19$14.88/sh+4,375$65,100→ 13,652 total
Sale
Stock Option (Right to Buy)
2022-01-19$26.09/sh−15,000$391,296→ 3,027 total

Footnotes (3)

[F1]The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2021.
[F2]Represents the weighted average sales price per share. The shares were sold at prices ranging from $26.05 to $26.15 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
[F3]All of the shares subject to this option are fully vested and exercisable as of the date hereof.

Documents

1 file